Anavex Life Sciences Corp. (0HFR.L)
USD 9.08
(-3.55%)
USD 9.08
(-3.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -55.75 Million USD | 12.68% |
| 2022 | -54.39 Million USD | -29.76% |
| 2021 | -41.92 Million USD | -36.29% |
| 2020 | -30.75 Million USD | -6.98% |
| 2019 | -28.75 Million USD | -49.87% |
| 2018 | -19.18 Million USD | -23.46% |
| 2017 | -15.53 Million USD | -4.45% |
| 2016 | -14.87 Million USD | -109.27% |
| 2015 | -7.1 Million USD | -139.43% |
| 2014 | -2.96 Million USD | -39.19% |
| 2013 | -2.13 Million USD | 50.64% |
| 2012 | -4.32 Million USD | 30.08% |
| 2011 | -6.18 Million USD | -9.42% |
| 2010 | -5.64 Million USD | -19.31% |
| 2009 | -4.73 Million USD | 10.17% |
| 2008 | -5.26 Million USD | -233.97% |
| 2007 | -1.57 Million USD | -6065.93% |
| 2006 | -25.59 Thousand USD | 72.04% |
| 2005 | -91.54 Thousand USD | -532.8% |
| 2004 | -14.46 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -12.51 Million USD | -46.64% |
| 2024 Q1 | -8.53 Million USD | 32.53% |
| 2024 Q3 | -14.72 Million USD | -17.65% |
| 2023 Q3 | -13.53 Million USD | 4.64% |
| 2023 FY | -47.49 Million USD | 12.68% |
| 2023 Q2 | -14.18 Million USD | -9.22% |
| 2023 Q1 | -12.99 Million USD | 22.19% |
| 2023 Q4 | -12.65 Million USD | 6.49% |
| 2022 Q3 | -12.27 Million USD | 4.87% |
| 2022 Q1 | -11.72 Million USD | 4.31% |
| 2022 FY | -54.39 Million USD | -29.76% |
| 2022 Q4 | -16.69 Million USD | -35.98% |
| 2022 Q2 | -12.9 Million USD | -10.1% |
| 2021 Q3 | -11.35 Million USD | -26.96% |
| 2021 Q4 | -12.25 Million USD | -7.89% |
| 2021 FY | -41.92 Million USD | -36.29% |
| 2021 Q1 | -9.39 Million USD | -25.15% |
| 2021 Q2 | -8.94 Million USD | 4.81% |
| 2020 Q2 | -7.69 Million USD | -0.95% |
| 2020 FY | -30.75 Million USD | -6.98% |
| 2020 Q3 | -8.1 Million USD | -5.3% |
| 2020 Q4 | -7.5 Million USD | 7.38% |
| 2020 Q1 | -7.62 Million USD | -21.6% |
| 2019 Q2 | -8.06 Million USD | -9.01% |
| 2019 FY | -28.75 Million USD | -49.87% |
| 2019 Q1 | -7.39 Million USD | -27.25% |
| 2019 Q3 | -7.07 Million USD | 12.32% |
| 2019 Q4 | -6.27 Million USD | 11.33% |
| 2018 Q4 | -5.81 Million USD | -27.97% |
| 2018 Q3 | -4.54 Million USD | 4.03% |
| 2018 FY | -19.18 Million USD | -23.46% |
| 2018 Q1 | -4.09 Million USD | 20.97% |
| 2018 Q2 | -4.73 Million USD | -15.7% |
| 2017 Q1 | -3.13 Million USD | 52.2% |
| 2017 FY | -15.53 Million USD | -4.45% |
| 2017 Q3 | -3.63 Million USD | -1.22% |
| 2017 Q2 | -3.59 Million USD | -14.64% |
| 2017 Q4 | -5.17 Million USD | -42.39% |
| 2016 Q4 | -6.55 Million USD | -191.88% |
| 2016 Q1 | -3.92 Million USD | 1.12% |
| 2016 FY | -14.87 Million USD | -109.27% |
| 2016 Q2 | -2.15 Million USD | 45.1% |
| 2016 Q3 | -2.24 Million USD | -4.3% |
| 2015 FY | -7.1 Million USD | -139.43% |
| 2015 Q4 | -3.96 Million USD | -162.18% |
| 2015 Q3 | -1.51 Million USD | -76.27% |
| 2015 Q2 | -858.33 Thousand USD | -11.37% |
| 2015 Q1 | -770.67 Thousand USD | -20.54% |
| 2014 Q4 | -639.36 Thousand USD | 35.99% |
| 2014 Q3 | -998.83 Thousand USD | 2.19% |
| 2014 Q2 | -1.02 Million USD | -230.58% |
| 2014 FY | -2.96 Million USD | -39.19% |
| 2014 Q1 | -308.9 Thousand USD | 78.93% |
| 2013 Q1 | -415.37 Thousand USD | 35.83% |
| 2013 FY | -2.13 Million USD | 50.64% |
| 2013 Q4 | -1.46 Million USD | -1070.18% |
| 2013 Q2 | -126.4 Thousand USD | 69.57% |
| 2013 Q3 | -125.27 Thousand USD | 0.89% |
| 2012 Q3 | -696.34 Thousand USD | 12.37% |
| 2012 Q4 | -647.34 Thousand USD | 7.04% |
| 2012 FY | -4.32 Million USD | 30.08% |
| 2012 Q2 | -794.65 Thousand USD | 63.69% |
| 2012 Q1 | -2.18 Million USD | -78.43% |
| 2011 Q3 | -1.63 Million USD | 15.87% |
| 2011 Q1 | -1.36 Million USD | 30.39% |
| 2011 FY | -6.18 Million USD | -9.42% |
| 2011 Q4 | -1.22 Million USD | 25.08% |
| 2011 Q2 | -1.94 Million USD | -42.34% |
| 2010 FY | -5.64 Million USD | -19.31% |
| 2010 Q4 | -1.96 Million USD | -50.74% |
| 2010 Q3 | -1.3 Million USD | 14.22% |
| 2010 Q2 | -1.51 Million USD | -76.07% |
| 2010 Q1 | -862.59 Thousand USD | 52.11% |
| 2009 Q1 | -906.72 Thousand USD | 61.31% |
| 2009 Q2 | -783.7 Thousand USD | 13.57% |
| 2009 Q3 | -1.25 Million USD | -60.46% |
| 2009 Q4 | -1.8 Million USD | -43.23% |
| 2009 FY | -4.73 Million USD | 10.17% |
| 2008 Q3 | -1.33 Million USD | -99.11% |
| 2008 Q2 | -671.73 Thousand USD | 26.75% |
| 2008 FY | -5.26 Million USD | -233.97% |
| 2008 Q1 | -917.02 Thousand USD | 19.61% |
| 2008 Q4 | -2.34 Million USD | -75.22% |
| 2007 Q3 | -255.56 Thousand USD | -51.42% |
| 2007 FY | -1.57 Million USD | -6065.93% |
| 2007 Q2 | -168.78 Thousand USD | -1267.88% |
| 2007 Q4 | -1.14 Million USD | -346.37% |
| 2007 Q1 | -12.33 Thousand USD | -111.1% |
| 2006 Q3 | -5680.00 USD | -21.89% |
| 2006 Q4 | -5845.00 USD | -2.9% |
| 2006 FY | -25.59 Thousand USD | 72.04% |
| 2006 Q1 | -9407.00 USD | 77.47% |
| 2006 Q2 | -4660.00 USD | 50.46% |
| 2005 FY | -91.54 Thousand USD | -532.8% |
| 2005 Q3 | -45.69 Thousand USD | 0.0% |
| 2005 Q2 | -45.69 Thousand USD | -1015.13% |
| 2005 Q4 | -41.74 Thousand USD | 8.65% |
| 2005 Q1 | -4098.00 USD | 0.0% |
| 2004 FY | -14.46 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 67.044% |
| Dynavax Technologies Corporation | -37.02 Million USD | -50.578% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -958.189% |
| Perrigo Company plc | 151.9 Million USD | 136.706% |
| Illumina, Inc. | -1.06 Billion USD | 94.784% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.813% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 87.894% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.604% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.82% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 49.595% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.378% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -24.826% |
| Waters Corporation | 817.67 Million USD | 106.819% |
| Biogen Inc. | 1.29 Billion USD | 104.3% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 79.651% |
| Evolus, Inc. | -49.23 Million USD | -13.249% |
| Adicet Bio, Inc. | -152.03 Million USD | 63.328% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 54.108% |
| bluebird bio, Inc. | -244.26 Million USD | 77.174% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 64.159% |
| FibroGen, Inc. | -281.81 Million USD | 80.215% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 104.13% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -23.69% |
| Homology Medicines, Inc. | -48.25 Million USD | -15.545% |
| Geron Corporation | -193.94 Million USD | 71.251% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 80.241% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 24.135% |
| Myriad Genetics, Inc. | -123.7 Million USD | 54.926% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 44.701% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 89.18% |
| Zoetis Inc. | 3.06 Billion USD | 101.817% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -15.676% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 105.128% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 128.675% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.294% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -42.405% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 84.238% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 79.799% |
| Verastem, Inc. | -92.08 Million USD | 39.451% |
| Nektar Therapeutics | -137.42 Million USD | 59.428% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 75.949% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 42.73% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 79.182% |
| OPKO Health, Inc. | -157.02 Million USD | 64.491% |
| Exelixis, Inc. | 170.88 Million USD | 132.628% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 122.222% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 151.971% |
| uniQure N.V. | -282.87 Million USD | 80.289% |
| Imunon, Inc. | -21.03 Million USD | -165.121% |
| Blueprint Medicines Corporation | -486.27 Million USD | 88.534% |
| Insmed Incorporated | -709.62 Million USD | 92.143% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 116.517% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 85.758% |
| TG Therapeutics, Inc. | 20.63 Million USD | 370.227% |
| Incyte Corporation | 620.52 Million USD | 108.985% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 92.324% |